Academic Journals Database
Disseminating quality controlled scientific knowledge

Conestat alfa for the treatment of angioedema attacks

Author(s): Davis B | Bernstein JA

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2011;
Issue: default;
Start page: 265;
Date: 2011;
Original page

Benjamin Davis, Jonathan A BernsteinUniversity of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section, Cincinnati, OH, USAAbstract: Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its current treatment modalities and focuses on findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement products because it is produced from transgenic rabbits rather than derived from human plasma donors, which can potentially allow an unlimited source of drug without any concern of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is safe and effective for the treatment of acute HAE attacks.Keywords: androgens, adverse events, patients, HAE attacksĀ 

Tango Rapperswil
Tango Rapperswil

     Save time & money - Smart Internet Solutions